Michael Lock

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4206799/publications.pdf

Version: 2024-02-01

١			186254	98792
	88	4,820	28	67
	papers	citations	h-index	g-index
ľ				
	90	90	90	5462
	all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cancer-related fatigueâ€"pharmacological interventions: systematic review and network meta-analysis. BMJ Supportive and Palliative Care, 2023, 13, 274-280.	1.6	8
2	Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer – a systematic review and network meta-analysis of survival data. Acta Oncológica, 2022, 61, 484-494.	1.8	9
3	Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications. Critical Reviews in Oncology/Hematology, 2022, 169, 103566.	4.4	8
4	Comparing treatment modalities for hepatocellular carcinoma: the value of network meta-analyses. Acta Oncol $ ilde{A}^3$ gica, 2022, 61, 495-495.	1.8	2
5	Does stereotactic body radiation improve outcomes compared to conventional radiation for liver cancer patients?. Clinical and Translational Radiation Oncology, 2022, 35, 17-20.	1.7	1
6	Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Supportive Care in Cancer, 2021, 29, 3439-3459.	2.2	18
7	Weight changes of younger and older early breast cancer patients—a meta regression. Annals of Palliative Medicine, 2021, 10, 0-0.	1.2	1
8	Intrafraction motion monitoring to determine PTV margins in early stage breast cancer patients receiving neoadjuvant partial breast SABR. Radiotherapy and Oncology, 2021, 158, 276-284.	0.6	3
9	Esophageal Cancer Radiotherapy Dose Escalation Meta Regression Commentary: "High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis― Frontiers in Oncology, 2021, 11, 700300.	2.8	5
10	Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Supportive Care in Cancer, 2021, 29, 4269-4275.	2.2	8
11	Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care in Cancer, 2020, 28, 2095-2103.	2.2	30
12	Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis. Supportive Care in Cancer, 2020, 28, 2071-2078.	2.2	37
13	DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR. Clinical and Translational Radiation Oncology, 2020, 21, 25-31.	1.7	12
14	Inter-rater reliability in performance status assessment between clinicians and patients: a systematic review and meta-analysis. BMJ Supportive and Palliative Care, 2020, 10, 129-135.	1.6	10
15	Enteral and parenteral nutrition in cancer patients, a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Supportive Care in Cancer, 2020, 28, 979-1010.	2.2	22
16	Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial. BMC Cancer, 2020, 20, 978.	2.6	9
17	The Effect of Registration on Voxel-Wise Tofts Model Parameters and Uncertainties from DCE-MRI of Early-Stage Breast Cancer Patients Using 3DSlicer. Journal of Digital Imaging, 2020, 33, 1065-1072.	2.9	6
18	Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials. Annals of Palliative Medicine, 2020, 9, 3716-3720.	1.2	5

#	Article	IF	Citations
19	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 2020, 38, 2830-2838.	1.6	683
20	Stereotactic ablative radiotherapy for the comprehensive treatment of $4\hat{a} \in 10$ oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 2019, 19, 816.	2.6	165
21	Prostate Cancer, Gender Identity, and Testosterone Replacement Therapy in Klinefelter Syndrome: A Case Report and Literature Review. Cureus, 2019, 11, e4630.	0.5	4
22	Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. Radiotherapy and Oncology, 2019, 141, 56-61.	0.6	71
23	Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 142, 164-186.	4.4	2
24	A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis. Advances in Radiation Oncology, 2019, 4, 668-673.	1.2	15
25	Symptom clusters in patients with breast cancer receiving radiation therapy. European Journal of Oncology Nursing, 2019, 42, 14-20.	2.1	29
26	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, 943-947.	0.8	46
27	Symptoms Predictive of Overall Quality of Life Using the Edmonton Symptom Assessment Scale in Breast Cancer Patients Receiving Radiotherapy. Clinical Breast Cancer, 2019, 19, 405-410.	2.4	19
28	Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet, The, 2019, 393, 2051-2058.	13.7	1,333
29	Reducing the dose of gadolinium-based contrast agents for DCE-MRI guided SBRT: The effects on inter and intra observer variability for preoperative target volume delineation in early stage breast cancer patients. Radiotherapy and Oncology, 2019, 131, 60-65.	0.6	7
30	Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Post-lumpectomy Patients with Breast Cancer Receiving Adjuvant Radiation Therapy. Cureus, 2019, 11, e4807.	0.5	6
31	The Utility of Penile Bulb Contouring to Localise the Prostate Apex as Compared to Urethrography. Journal of Medical Imaging and Radiation Sciences, 2018, 49, 76-83.	0.3	3
32	Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer. JAMA Oncology, 2018, 4, e180039.	7.1	238
33	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. Technology in Cancer Research and Treatment, 2018, 17, 153303381879021.	1.9	53
34	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Research and Treatment, 2018, 172, 371-379.	2.5	9
35	Patient-perceived barriers to radiation therapy for breast cancer?. Canadian Journal of Surgery, 2018, 61, 141-143.	1.2	7
36	Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate. Cureus, 2018, 10, e3435.	0.5	0

#	Article	IF	CITATIONS
37	Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy. Cureus, 2018, 10, e3714.	0.5	1
38	Potential benefit of rotational radiation therapy. Future Oncology, 2017, 13, 873-874.	2.4	2
39	Reducing Patient Waiting Times for Radiation Therapy and Improving the Treatment Planning Process: a Discrete-event Simulation Model (Radiation Treatment Planning). Clinical Oncology, 2017, 29, 385-391.	1.4	39
40	Stereotactic Body Radiotherapy. Medical Radiology, 2017, , 323-395.	0.1	0
41	Lessons Learned From the Two-Step QA Process in NRG Oncology/RTOG 1005, A Phase 3 Trial for Early-Stage Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, S216-S217.	0.8	0
42	A multivariable model to predict survival for patients with hepatic carcinoma or liver metastasis receiving radiotherapy. Future Oncology, 2017, 13, 19-30.	2.4	11
43	Advances in external beam stereotactic body radiotherapy: principle concerns in implementing a liver radiation program. Chinese Clinical Oncology, 2017, 6, S13-S13.	1.2	2
44	Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World Journal of Hepatology, 2017, 9, 645.	2.0	9
45	Predicting which patients actually receive radiation following breast conserving therapy in Canadian populations. Canadian Journal of Surgery, 2016, 59, 358-360.	1.2	4
46	Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncology, 2016, 12, 2729-2739.	2.4	9
47	Postediting prostate magnetic resonance imaging segmentation consistency and operator time using manual and computer-assisted segmentation: multiobserver study. Journal of Medical Imaging, 2016, 3, 046002.	1.5	3
48	Evaluation of Health Economics in Radiation Oncology: A Systematic Review. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1006-1014.	0.8	20
49	Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Review of Anticancer Therapy, 2016, 16, 523-530.	2.4	28
50	A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy. Cureus, 2016, 8, e555.	0.5	0
51	Sci-Fri AM: MRI and Diagnostic Imaging - 03: The influence of sampling percentage in deformable registration on kinetic model analysis results in DCE-MRI of the breast. Medical Physics, 2016, 43, 4951-4951.	3.0	0
52	Abscopal Effects: Case Report and Emerging Opportunities. Cureus, 2015, 7, e344.	0.5	25
53	A phase II trial to evaluate single-dose stereotactic body radiation therapy (SBRT) prior to surgery for early-stage breast carcinoma: SIGNAL (stereotactic image-guided neoadjuvant ablative radiation then) Tj ETQq1	1 0078431	4 ngBT /Over
54	A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 856-862.	0.8	63

#	Article	IF	CITATIONS
55	The development of stereotactic body radiotherapy in the past decade: a global perspective. Future Oncology, 2015, 11, 2721-2733.	2.4	8
56	Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review Cureus, 2015, 7, e364.	0.5	14
57	Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncology, 2014, 10, 2227-2241.	2.4	15
58	Spatially varying accuracy and reproducibility of prostate segmentation in magnetic resonance images using manual and semiautomated methods. Medical Physics, 2014, 41, 113503.	3.0	16
59	Assessment of contrast enhanced respiration managed cone-beam CT for image guided radiotherapy of intrahepatic tumors. Medical Physics, 2014, 41, 051905.	3.0	9
60	Dynamic contrast enhanced CT aiding gross tumor volume delineation of liver tumors: An interobserver variability study. Radiotherapy and Oncology, 2014, 111, 153-157.	0.6	34
61	In Regard to Parikh etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 90, 716-717.	0.8	4
62	The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far?. Journal of Gastrointestinal Oncology, 2014, 5, 236-46.	1.4	27
63	Prediction and Reduction of Motion Artifacts in Free-Breathing Dynamic Contrast Enhanced CT Perfusion Imaging of Primary and Metastatic Intrahepatic Tumors. Academic Radiology, 2013, 20, 414-422.	2.5	13
64	The Impact of Post-Mastectomy Radiation Therapy on Male Breast Cancer Patientsâ€"A Case Series. International Journal of Radiation Oncology Biology Physics, 2012, 82, 696-700.	0.8	44
65	Radiotherapy for Liver Metastases: A Review of Evidence. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1047-1057.	0.8	172
66	Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. BMC Cancer, 2012, 12, 305.	2.6	207
67	Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clinical and Translational Oncology, 2012, 14, 150-156.	2.4	36
68	Brachytherapy with permanent gold grain seeds for squamous cell carcinoma of the lip. Radiotherapy and Oncology, 2011, 98, 352-356.	0.6	12
69	Radiation recall dermatitis due to gemcitabine does not suggest the need to discontinue chemotherapy. Oncology Letters, 2011, 2, 85-90.	1.8	19
70	Technology assessment of automated atlas based segmentation in prostate bed contouring. Radiation Oncology, 2011, 6, 110.	2.7	45
71	Phase I Trial of Simultaneous In-Field Boost With Helical Tomotherapy for Patients With One to Three Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1128-1133.	0.8	47
72	A Phase II Trial of Arc-Based Hypofractionated Intensity-Modulated Radiotherapy in Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1306-1315.	0.8	37

#	Article	IF	CITATIONS
73	Effective and cost-effective clinical trial recruitment strategies for postmenopausal women in a community-based, primary care setting. Contemporary Clinical Trials, 2010, 31, 447-456.	1.8	17
74	Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry Part B - Clinical Cytometry, 2009, 76B, 107-117.	1.5	22
75	Salvage radiotherapy following radical prostatectomy. International Journal of Urology, 2009, 16, 31-36.	1.0	10
76	Systematic review of dose–volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiotherapy and Oncology, 2009, 91, 282-287.	0.6	96
77	Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer. Radiation Oncology, 2008, 3, 1.	2.7	31
78	Gabapentin for the treatment of menopausal hot flashes. Menopause, 2008, 15, 310-318.	2.0	101
79	Minimal decrease in hot flashes desired by postmenopausal women in family practice. Menopause, 2007, 14, 203-207.	2.0	35
80	Psychometric properties of a prostate cancer radiation late toxicity questionnaire. Health and Quality of Life Outcomes, 2007, 5, 29.	2.4	6
81	A Prospective Evaluation of Helical Tomotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 632-641.	0.8	51
82	A comparison of prostate IMRT and helical tomotherapy class solutions. Radiotherapy and Oncology, 2006, 80, 374-377.	0.6	37
83	Prostate contouring uncertainty in megavoltage computed tomography images acquired with a helical tomotherapy unit during image-guided radiation therapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 595-607.	0.8	68
84	High-precision radiotherapy: where are we going and how do we get there?. Canadian Journal of Urology, 2006, 13 Suppl 2, 34-6.	0.0	0
85	Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies. International Journal of Radiation Oncology Biology Physics, 2005, 61, 830-841.	0.8	51
86	Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 104-110.	0.8	39
87	Prediction of radiation pneumonitis by dose–volume histogram parameters in lung cancer—a systematic review. Radiotherapy and Oncology, 2004, 71, 127-138.	0.6	384
88	Prophylaxis and treatment of cancer-related dyspnea with pharmacologic agents: A systematic review and network meta-analysis. Palliative and Supportive Care, 0, , 1-8.	1.0	3